Endo (ENDP) Ratings Placed on Review for Downgrade by Moody's Following Par Pharma Announcement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Piper Jaffray Raises Price Target on Endo Int'l (ENDP) Leading up to Par Pharma Acquisition
May 19, 2015 7:42 AM EDTPiper Jaffray reiterates an Overweight rating on Endo International plc (NASDAQ: ENDP), and raised the price target to $117.00 (from $110.00), leading up to the Par Pharmaceuticals acquisition. Endo plans on Acquiring Par for $8B.
Piper Jaffray analyst David Amsellem commented on Endo, saying, "Endo is... More
